1-4 of 4
Tommy Fu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy

Naveen Pemmaraju, MD, Boyd Mudenda, MD MSc, MBBChir, Cunlin Wang, MD, Jiao JI, PhD MD, Ming Lu, PhD, Tommy Fu, PhD, Eric Liang, PhD, Sasha McClain, PharmD, Piyush Sheladia, MS, Srdan Verstovsek, MD PhD, Dajun Yang, MD PhD, Yifan Zhai, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-137260
Published: 2020
Journal Articles

Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients

Qian Shi, PhD, Norbert Schmitz, MD, PhD, Christopher Flowers, MD MS, Fang-Shu Ou, PhD, David Cunningham, Michael Pfreundschuh, MD, John F Seymour, Ulrich Jaeger, Thomas M. Habermann, MD, Corinne Haioun, MD PhD, Hervé Tilly, MD PhD, Herve Ghesquieres, MD PhD, Francesco Merli, Marita Ziepert, Raoul Herbrecht, MD, Jocelyne Flament, MD, Tommy Fu, PhD, Bertrand Coiffier, MD PhD, Daniel Sargent, PhD
Journal: Blood
Blood (2016) 128 (22): 4196.
https://doi.org/10.1182/blood.V128.22.4196.4196
Published: 2016
Journal Articles

Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients

Matthew J Maurer, MS, Thomas M. Habermann, MD, Qian Shi, PhD, Norbert Schmitz, MD, PhD, David Cunningham, Michael Pfreundschuh, MD, PhD, John F. Seymour, MD, Ulrich Jaeger, Corinne Haioun, MD PhD, Hervé Tilly, MD PhD, Herve Ghesquieres, MD PhD, Francesco Merli, Marita Ziepert, Raoul Herbrecht, MD, Jocelyne Flament, MD, Tommy Fu, PhD, Christopher Flowers, MDMS, Fang-Shu Ou, PhD, Daniel Sargent, PhD, Bertrand Coiffier, MD PhD
Journal: Blood
Blood (2016) 128 (22): 3027.
https://doi.org/10.1182/blood.V128.22.3027.3027
Published: 2016
Journal Articles

Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004)

Pierre Fenaux, MD, PhD, Aristotles Giagounidis, MD, Odile Beyne-Rauzy, MD, PhD, Ghulam Mufti, MD, DM, FRCP, FRCPath, Moshe Mittelman, MD, Petra Muus, MD, PhD, Peter te Boekhorst, MD, PhD, Guillermo Sanz, MD, PhD, Mario Cazzola, MD, Jay Backstrom, MD, Tommy Fu, PhD, Eva Hellström-Lindberg, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 4027.
https://doi.org/10.1182/blood.V116.21.4027.4027
Published: 2010